DSGN
HealthcareDesign Therapeutics, Inc. · Biotechnology · $690M
What is Design Therapeutics, Inc.?
Design Therapeutics is a preclinical-stage biopharmaceutical company focused on developing treatments for rare genetic diseases driven by nucleotide repeat expansions. Headquartered in Carlsbad, California, the company is building a pipeline targeting conditions with few or no approved therapies.
The company develops small-molecule therapies designed to address the root genetic causes of repeat expansion diseases. Its lead programs target Friedreich Ataxia and Myotonic Dystrophy Type-1. Beyond these, the broader GeneTAC platform is being applied to additional conditions including Fragile X syndrome, Huntington disease, and ALS. Revenue generation has not yet begun, as the company remains in the preclinical research phase.
Design Therapeutics was incorporated in 2017 and is based in Carlsbad, California.
- Friedreich Ataxia program targeting mitochondrial dysfunction
- Myotonic Dystrophy Type-1 (DM1) neuromuscular disease program
- GeneTAC platform for nucleotide repeat expansion diseases
- Pipeline candidates for Huntington disease, ALS, and Fragile X syndrome
Is DSGN a Good Stock to Buy?
UQS Score rates DSGN as Poor overall, reflecting the early-stage nature and significant uncertainties inherent to preclinical biopharmaceutical development.
The Risk pillar stands out as the relative bright spot in DSGN's profile, suggesting the company maintains a financial position that provides some runway — a meaningful consideration for a pre-revenue biotech.
Quality, Moat, and Growth all register as Weak, consistent with a company that has no commercial products, no revenue, and an unproven platform. Valuation is rated Elevated, meaning the current market price reflects significant future expectations.
See the full pillar breakdown and underlying financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does DSGN pay dividends?
No — Design Therapeutics, Inc. does not currently pay a dividend.
Design Therapeutics does not pay a dividend, which is typical for preclinical-stage biotechs. All available capital is directed toward research, pipeline development, and clinical advancement. Income-focused investors should look elsewhere; DSGN is a pure research-stage bet on scientific and regulatory outcomes.
When does DSGN report earnings?
Design Therapeutics reports financial results on a quarterly cadence, standard for US-listed companies.
As a preclinical company, quarterly reports center on cash burn, operating expenses, and pipeline updates rather than revenue or profit. Progress disclosures around research milestones tend to be the most market-moving elements of each report.
For the most recent quarter's results and pipeline updates, visit Design Therapeutics' investor relations page directly.
What if I invested in Design Therapeutics, Inc.?
Based on Design Therapeutics, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
DSGN Long-term Outlook
With Growth and Quality both rated Weak, the near-term fundamental outlook for DSGN is constrained by the absence of clinical data and commercial revenue. The path to value creation runs entirely through pipeline advancement. A Good Risk rating provides some buffer, but the Elevated Valuation label signals that the market has already priced in meaningful future success — leaving limited margin for setbacks.
Growth drivers
- Advancement of Friedreich Ataxia and DM1 programs into clinical stages
- Expansion of the GeneTAC platform across additional rare disease indications
- Potential partnerships or licensing deals that validate the platform
Key risks
- Preclinical failure or delays before reaching human trials
- Elevated valuation leaves little room for pipeline disappointments
- Ongoing cash consumption with no near-term revenue to offset burn
DSGN vs Peers
DSGN operates in a competitive rare-disease biotech space alongside other small-cap companies pursuing specialized genetic and molecular targets.
ARS Pharmaceuticals focuses on acute allergic reaction treatments, representing a different therapeutic area and a more advanced commercial stage than DSGN's preclinical pipeline.
MeiraGTx pursues gene therapy approaches across ocular and neurological diseases, sharing DSGN's rare-disease focus but using a distinct gene-delivery technology platform.
CytomX develops conditionally activated antibody therapies for oncology, competing for similar small-cap biotech investor attention despite targeting a different disease category.
Frequently Asked Questions
What does Design Therapeutics do?
Design Therapeutics develops small-molecule therapies for rare genetic diseases caused by nucleotide repeat expansions. Its programs target conditions like Friedreich Ataxia and Myotonic Dystrophy Type-1, with a broader platform called GeneTAC being explored across diseases including Huntington disease, ALS, and Fragile X syndrome. The company is currently in the preclinical stage.
Does DSGN pay dividends?
No, Design Therapeutics does not pay a dividend. As a preclinical-stage biotech with no commercial revenue, the company directs its capital toward research and pipeline development. Dividend income is not part of the DSGN investment thesis at this stage.
When does DSGN report earnings?
Design Therapeutics follows a standard quarterly reporting cadence for US-listed companies. Because it is pre-revenue, reports focus on operating expenses and pipeline progress rather than sales figures. Check the company's investor relations page for the latest schedule and results.
Is DSGN a good stock to buy?
UQS Score rates DSGN as Poor overall, driven by Weak scores across Quality, Moat, and Growth, alongside an Elevated Valuation. The relatively stronger Risk pillar offers some reassurance about near-term financial stability, but the overall profile reflects the high uncertainty typical of preclinical biotechs. The full pillar breakdown is available to Pro members.
Is DSGN overvalued?
UQS Score's Valuation pillar for DSGN is rated Elevated, meaning the current market price appears to embed significant expectations about future pipeline success. For a preclinical company with no revenue, this leaves limited cushion if research timelines slip or trial results disappoint.
How does DSGN compare to its competitors?
Among the small-cap biotech peers tracked alongside DSGN — including ARS Pharmaceuticals, MeiraGTx, and CytomX Therapeutics — each pursues distinct therapeutic approaches and disease areas. DSGN's differentiation lies in its GeneTAC platform targeting nucleotide repeat expansion diseases specifically. UQS Score provides side-by-side pillar comparisons for Pro members.
What is DSGN's market cap bracket?
Design Therapeutics is classified as a small-cap stock. This places it in a segment of the market characterized by higher volatility and risk relative to mid- or large-cap peers, but also the potential for outsized returns if pipeline programs advance successfully.
Who founded Design Therapeutics?
Design Therapeutics was incorporated in 2017 and is headquartered in Carlsbad, California. For detailed founding history and leadership background, the company's official website and SEC filings are the most reliable sources.
Is DSGN a long-term quality investment?
As a long-term quality indicator, UQS Score currently rates DSGN as Poor, reflecting weak fundamentals across most pillars. Long-term quality investing typically favors companies with durable moats and consistent earnings — characteristics DSGN has not yet established as a preclinical-stage company. Pipeline progress could change this picture over time.
What is the main competitive advantage of Design Therapeutics?
Design Therapeutics' potential edge lies in its GeneTAC platform, a proprietary approach to targeting nucleotide repeat expansion diseases at the genetic level. If validated clinically, this platform could address multiple rare diseases with a single underlying technology. However, the Moat pillar is currently rated Weak, reflecting that this advantage remains unproven.
Unlock Full DSGN Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the exact UQS pillar scores across Quality, Growth, Moat, Risk, and Valuation
- ✓Access underlying financial metrics driving each pillar rating
- ✓Compare DSGN side-by-side with biotech peers on a standardized scoring framework
- ✓Track score changes as pipeline milestones and quarterly results arrive
- ✓See how DSGN ranks within the broader Healthcare sector universe
Pro Analysis
DSGN — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 7, 2026 | 13.8 | 0.0 | 11.0 | 0.0 | 74.0 | 0.0 | +0.1 |
| Apr 2, 2026 | 13.7 | 0.0 | 11.0 | 0.0 | 73.2 | 0.0 | — |
DSGN — Pillar Breakdown
Quality
— 0.0/100 (25%)Design Therapeutics, Inc. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Free cash flow relative to market value.
Growth
— 0.0/100 (20%)Design Therapeutics, Inc. faces growth headwinds with declining or stagnant revenue trends.
Revenue trajectory over the last twelve months.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Risk
— 74.0/100 (15%)Design Therapeutics, Inc. maintains a reasonable risk profile with manageable debt levels.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 0.0/100 (15%)Design Therapeutics, Inc. appears expensively valued relative to its fundamentals and growth prospects.
Moat
— 11/100 (25%)Design Therapeutics, Inc. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for DSGN.
Score Composition
Financial Data
More Stock Analysis
How is the DSGN UQS Score Calculated?
The UQS (Unified Quality Score) for Design Therapeutics, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Design Therapeutics, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Design Therapeutics, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.